DataJoint Adds Industry Veteran Dave Schuette to Board

Schuette brings over 25 years of experience transforming organizations in pharma, tech, and consulting

Mar. 12, 2026 at 11:21pm

Got story updates? Submit your updates here. ›

DataJoint, a scientific data infrastructure company enabling AI in regulated R&D, announced that Dave Schuette has joined its Board of Directors as an independent member. Schuette is the founder and managing partner of Slide3, a boutique consulting firm serving pharmaceutical, financial services, and technology clients. He brings over 25 years of experience as a business management executive, with a track record of transforming organizations and creating disruptive operational strategies.

Why it matters

DataJoint's appointment of Schuette to its board signals the company's focus on expanding into the pharmaceutical and life sciences markets, following the recent launch of its Agentic AI platform. Schuette's expertise in bridging scientific rigor with operational agility is expected to help DataJoint accelerate its mission of enabling trustworthy scientific AI.

The details

Prior to founding Slide3 in 2018, Schuette served as EVP and President of the Enterprise Business Unit at Synchronoss Technologies, leading growth across healthcare and life sciences. He was a founding partner of Knowledgent, a data and analytics firm acquired by Accenture, and held senior roles at BusinessEdge Solutions, acquired by EMC. Schuette also brings direct pharma industry experience, including work with Bristol-Myers Squibb.

  • DataJoint announced Schuette's appointment on March 12, 2026.

The players

Dave Schuette

The founder and managing partner of Slide3, a boutique consulting firm serving pharmaceutical, financial services, and technology clients. He has over 25 years of experience as a business management executive, with a track record of transforming organizations and creating disruptive operational strategies.

DataJoint

A scientific data infrastructure company headquartered in Houston, Texas, that enables defensible and reproducible AI in regulated R&D.

Jim Olson

The CEO of DataJoint.

Slide3

A boutique consulting firm helping companies in pharma, financial services, and technology navigate complex markets.

Got photos? Submit your photos here. ›

What they’re saying

“Dave's expertise in pharma and technology, and his ability to help companies scale with clarity and purpose, are exactly what DataJoint needs at this inflection point. His experience bridging scientific rigor with operational agility makes him an invaluable addition to our board.”

— Jim Olson, CEO of DataJoint (PR Newswire)

“DataJoint has built something genuinely differentiated — a platform that makes AI-ready data a reality, not just an aspiration. I'm proud to join the board and help accelerate its mission at a time when trustworthy scientific AI has never mattered more.”

— Dave Schuette (PR Newswire)

The takeaway

DataJoint's appointment of industry veteran Dave Schuette to its board signals the company's focus on expanding into the pharmaceutical and life sciences markets, leveraging Schuette's expertise in bridging scientific rigor with operational agility to help accelerate its mission of enabling trustworthy scientific AI.